Abstract: Although maximal safe surgery and adjuvant Stupp protocols are the first line treatment of glioblastoma (GBM) recommended by several guidelines, patients >70 years old are excluded from this protocol. No identical treatment exists for elderly patients who account for nearly 50% of all cases. Elderly patients do not receive standard treatment because of certain reasons, including low physical fitness score, multiple comorbidities, and social and family factors. Hence, the prognosis of the elderly is poor. Many clinical trials have emerged to analyze GBM in elderly patients. This review describes the molecular features and new clinical trials of elderly GBM to provide medical evidence for the individualized treatment of elderly patients.